Levi & Korsinsky notifies investors that it has commenced an investigation into Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) concerning potential violations of the federal securities laws.
Bolt announced in a press release on May 14, 2024, that the Company would "cease further development of trastuzumab imbotolimod (BDC-1001)", Bolt's lead asset, "and reduce workforce by approximately 50%". Following Bolt's announcement, multiple analysts downgraded the Company's stock. Following this news, Bolt's stock dropped over 18% on May 15, 2024.
If you suffered a loss on your Bolt Biotherapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





